Topotecan HCl | DNA topoisomerase I inhibitor

Available Options

Size:PriceQuantity 
10 mg$42.00
50 mg$160.00
Request Quote / Bulk / Custom Size
Product Inquiry

Topotecan HCl (119413-54-6) is a water-soluble and orally active analog of camptothecin, a DNA topoisomerase I inhibitor.1 Inhibits topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells, IC50s = 13 and 2 nM respectively.2 Downregulates B-Myb and MycN expression in neuroblastoma cells.3 A clinically useful anticancer agent.

References/Citations:

  1. Schellens et al. (1996), Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor; Br. J. Cancer 73 1268
  2. Caceres et al. (2003), Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors; Anticancer Drugs 14 569
  3. Sottile et al. (2012), A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma; Oncotarget 3 535
119413-54-6, DNA topoisomerase I inhibitor, NSC 609669, NSC609669, SKF-104864A, SKF104864A, Topoisomerase I inhibitor, Topotecan, topotecan HCl, Topotecan supplier
Alternate Name:
NSC 609669; SKF-104864A

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Topotecan HCl (119413-54-6) is a water-soluble and orally active analog of camptothecin, a DNA topoisomerase I inhibitor.1 Inhibits topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells, IC50s = 13 and 2 nM respectively.2 Downregulates B-Myb and MycN expression in neuroblastoma cells.3 A clinically useful anticancer agent.

References/Citations:

  1. Schellens et al. (1996), Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor; Br. J. Cancer 73 1268
  2. Caceres et al. (2003), Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors; Anticancer Drugs 14 569
  3. Sottile et al. (2012), A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma; Oncotarget 3 535